ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Human Papillomavirus Recombinant Vaccine nonavalent

Also written as “V503”, “9vHPV Vaccine” and “9vHPV vaccine”.

Its studies are mostly in Papillomavirus Infections · Condylomata Acuminata · Uterine Cervical Neoplasms · Papilloma · Dengue, led by 5 companies.

Drug pageHuman Papillomavirus Recombinant Vaccine nonavalent: every studyMany companies study it; this page follows only the 25 they lead. All 74 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 21, 200925 company-led studies, 10 open or runningNext primary completion: Jan 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only207 open or runningphase 3since Jul 21, 2009Jul 21, 2009Jan 15, 2027phase 3 · NCT04199689
Shanghai Bovax Biotechnologyits history only21 open or runningphase 3since Jun 8, 2020Jun 8, 2020none ahead
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chairits history only11 open or runningearly phase 1since Apr 28, 2025Apr 28, 2025none ahead
Takedaits history only10 open or runningphase 3since Mar 16, 2020Mar 16, 2020none ahead
Xiamen Innovax Biotechits history only11 open or runningphase 4since Jun 16, 2026Jun 16, 2026Feb 28, 2027phase 4 · NCT07668271

Also a collaborator on its studies: Chongqing Bovax Biopharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Jul 21, 2009.

  1. Jun 21, 2019Phase 3 study in Papillomavirus InfectionsMerck · NCT03998254 · 6,000 enrolled · China
  2. Dec 12, 2019Phase 3 study in Papillomavirus InfectionsMerck · NCT04199689 · 6,033 enrolled · United States, Belgium, Brazil and more
  3. Mar 16, 2020Takeda’s first study: phase 3 study in DengueNew to TakedaTakeda · NCT04313244 · 614 enrolled · Thailand
  4. Jun 8, 2020Shanghai Bovax Biotechnology’s first study: phase 3 study in Uterine Cervical NeoplasmsNew to Shanghai Bovax BiotechnologyShanghai Bovax Biotechnology · NCT04425291 · 1,680 enrolled · China
  5. Nov 5, 2020Phase 3 study in Condylomata AcuminataMerck · NCT04635423 · 1,059 enrolled · Japan
  6. Jan 12, 2021Phase 3 study in Papillomavirus InfectionsMerck · NCT04708041 · 700 enrolled · United States, Colombia, Mexico and more
  7. Feb 23, 2021Phase 3 study in Papillomavirus InfectionsMerck · NCT04772534 · 314 enrolled · Japan
  8. May 17, 2021Phase 3 study in Papillomavirus InfectionsShanghai Bovax Biotechnology · NCT04895020 · 1,200 planned · China
  9. Nov 10, 2021Phase 3 study in Papillomavirus InfectionsMerck · NCT05119855 · 165 enrolled · United States
  10. Mar 8, 20222 phase 3 studiesMerck · NCT05285826, NCT05314023
  11. Jun 28, 2022Phase 3 study in Papillomavirus InfectionsMerck · NCT05450705 · 1,500 enrolled · China
  12. Apr 28, 2025Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair’s first study: early phase 1 study in Papillomavirus InfectionsNew to Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · NCT06959563 · 20 enrolled · United States
  13. Jun 16, 2026Xiamen Innovax Biotech’s first study: phase 4 study in Infection by Human Papilloma VirusNew to Xiamen Innovax BiotechXiamen Innovax Biotech · NCT07668271 · 720 planned · China
  14. Aug 21, 2026Phase 3 study in Papillomavirus InfectionsMerck · NCT07785843 · 930 planned · China

Ahead

  1. Jan 15, 2027Primary completion: phase 3 study in Papillomavirus InfectionsMerck · NCT04199689
  2. Feb 28, 2027Primary completion: phase 4 study in Infection by Human Papilloma VirusXiamen Innovax Biotech · NCT07668271
  3. Dec 18, 2027Primary completion: phase 3 study in Papillomavirus InfectionsMerck · NCT07785843
  4. Mar 31, 2028Primary completion: phase 3 study in Papillomavirus InfectionsMerck · NCT03998254

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07785843Papillomavirus Infections · China3RecruitingMerckDec 18, 2027930
NCT07668271Infection by Human Papilloma Virus · China4RecruitingXiamen Innovax BiotechFeb 28, 2027720
NCT06959563Papillomavirus Infections · United StatesEarly 1Active, not recruitingHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairOct 18, 202620
NCT05450705Papillomavirus Infections · China3Active, not recruitingMerckAug 3, 20291,500
NCT05314023Condylomata Acuminata · China3Active, not recruitingMerckFeb 19, 20291,590
NCT05285826Papillomavirus Infections · China3Active, not recruitingMerckMay 25, 20298,100
NCT05119855Papillomavirus Infections · United States3CompletedMerckDec 12, 2023165
NCT04895020Papillomavirus Infections · China3RecruitingShanghai Bovax BiotechnologyJan 13, 20231,200
NCT04772534Papillomavirus Infections · Japan3CompletedMerckApr 6, 2024314
NCT04708041Papillomavirus Infections · United States, Colombia, Mexico and more3Active, not recruitingMerckOct 23, 2029700
NCT04635423Condylomata Acuminata · Japan3CompletedMerckDec 31, 20231,059
NCT04425291Uterine Cervical Neoplasms · China3CompletedShanghai Bovax BiotechnologySep 6, 20211,680
NCT04313244Dengue · Thailand3CompletedTakedaFeb 21, 2022614
NCT04199689Papillomavirus Infections · United States, Belgium, Brazil and more3Active, not recruitingMerckJan 15, 20276,033
NCT03998254Papillomavirus Infections · China3Active, not recruitingMerckMar 31, 20286,000
NCT03903562Papillomavirus Infections · China3CompletedMerckFeb 28, 20251,990
NCT03546842Papillomavirus Infections · Vietnam3CompletedMerckJan 29, 2019201
NCT03158220Uterine Cervical Neoplasms · Austria, Belgium, Finland and more3CompletedMerckNov 19, 20181,212
NCT02114385Papillomavirus Infections · Belgium, Germany, Netherlands3CompletedMerckApr 22, 2015500
NCT01984697Papillomavirus Infections3CompletedMerckJun 19, 20151,518
NCT01651949Condylomata Acuminata3CompletedMerckAug 4, 20142,520
NCT01304498Human Papillomavirus3CompletedMerckDec 20, 2011600
NCT01254643Papillomavirus Infections3CompletedMerckAug 10, 2013100
NCT01047345Uterine Cervical Neoplasms3CompletedMerckJun 10, 2011924
NCT00943722Uterine Cervical Neoplasms3CompletedMerckApr 30, 20113,074

How it is read

Names in the registry

  • “V503”, 10 entries
  • “9vHPV Vaccine”, 5 entries
  • “9vHPV vaccine”, 5 entries
  • “9-valent HPV vaccine (Cecolin 9)”, 1 entry
  • “9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.